Search for content, post, videos

Toxicology Knowledge Team appoints new CEO

As of March 1, 2022, Suzanne Iverson Hemberg will succeed Elinor Hahne and be appointed the new CEO for Toxicology Knowledge Team AB (TKT) in Sweden.

Iverson Hemberg brings over 20 years of strong leadership as a Senior Scientist and Director of laboratory- and knowledge-based organisations in both public and private sectors in Canada and Sweden, states TKT. The majority of this time was spent in the pharmaceutical industry where she held positions in both DMPK and Safety Assessment arenas as Scientific Lead, Functional Project Leader or Section Director, often in parallel.

“We are delighted to appoint Suzanne as the new CEO for TKT. With her strong scientific background and track-record in leadership combined with her deep knowledge of drug development, TKT will be well equipped to achieve the strong growth that is projected during the next couple of years,” says Karin Meyer, Chairman of the Board of TKT. “I would also like to thank Elinor Hahne for her valuable contributions as CEO during the transition phase to the CTR-group.”

Suzanne Iverson Hemberg

Iverson Hemberg received her Ph.D. from the University of Toronto in 2002 in Pharmacology/Toxicology, then moved to Sweden for a postdoc in Molecular Toxicology in the Institute of Environmental Medicine at the Karolinska Institute. Iverson Hemberg is currently the Director of all Clinical Chemistry laboratories for the Region of Västra Götaland (except Skas).

“Whilst extremely proud of my years together with fantastic colleagues at Sahlgrenska University Hospital, I am eager to continue my life-long education in Toxicology together with recognised experts in the field. I also look forward to contributing my energy and passion for ensuring that industrial Toxicology and DMPK sciences remain strong in the Nordic region. I believe that TKT and Center for Translational Research are well-positioned to be the best possible partners in innovation for the benefit of Life Sciences in Sweden and ultimately public health, and I am excited to join them on their journey,” says Suzanne Iverson Hemberg.